You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(00867.HK)獲控股股東轉讓癲癇噴霧劑相關資產
阿思達克 08-29 09:26
康哲藥業(00867.HK)公布,與主席兼控股股東林剛全資持有的公司A&B達成資產轉讓協議,獲對方轉讓在中國大陸、香港、澳門及台灣,關於地西泮鼻噴霧劑(維圖可)的資產,包括上市許可、生產權、銷售權等。 根據轉讓協議,公司將以淨銷售額的9%向A&B支付許可費。另外承擔A&B於上游協議中的責任,支付每單位不超過0.6美元的許可費。 根據上市規則,持續關連交易的協議期限,必須固定且不得超過三年,公司認為使用長期或不固定期限,符合醫藥行業慣例,因為推廣藥物會投入大量時間和資金。據此,長達約25年的許可費期限可反映市場慣例,因此公司委任英高作為財務顧問,以解釋協議期限超過三年的原因。 地西泮鼻噴霧劑(維圖可)為中國首個地西泮鼻用噴霧劑,用於6歲及以上兒童和成人癲癇患者,叢集性癲癇發作/急性反復性癲癇發作的急性治療。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account